0001213900-21-046965 | 6-K | XBRL Viewer | Altamira Therapeutics LTD

Document And Entity Information	6 Months Ended
Document And Entity Information	Jun. 30, 2021
Document Information Line Items
Entity Registrant Name	Altamira Therapeutics Ltd.
Document Type	6-K
Current Fiscal Year End Date	--12-31
Amendment Flag	false
Entity Central Index Key	0001601936
Document Period End Date	Jun. 30, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2
Entity File Number	001-36582

Reporting Entity

6 Months Ended

Jun. 30, 2021

Reporting entity [Abstract]

Reporting entity

Reporting entity

Altamira Therapeutics Ltd. (formerly Auris Medical Holding Ltd.) (the “Company”) is an exempted company incorporated under the laws of Bermuda. The Company began its operations as a corporation organized in accordance with Swiss law and domiciled in Switzerland under the name Auris Medical Holding AG (“Auris Medical (Switzerland)”). Following shareholder approval at an extraordinary general meeting of shareholders held on March 8, 2019 and upon the issuance of a certificate of continuance by the Registrar of Companies in Bermuda on March 18, 2019, the Company discontinued as a Swiss company and, pursuant to Article 163 of the Swiss Federal Act on Private International Law and pursuant to Section 132C of the Companies Act 1981 of Bermuda (the “Companies Act”), continued existence under the Companies Act as a Bermuda company with the name “Auris Medical Holding Ltd.” (the “Redomestication”). On March 18, 2019, the common shares of the Company began trading on the Nasdaq Capital Market under the trading symbol “EARS”. The Company’s registered office is located at Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda. On May 1, 2019, the Company effected a one-for-twenty reverse share split (the “2019 Reverse Share Split”) of the Company’s issued and outstanding common shares. Unless indicated or the context otherwise requires, all per share amounts and numbers of common shares in this report have been retrospectively adjusted for the 2019 Reverse Share Split. On July 21, 2021, the Company changed its name to Altamira Therapeutics Ltd. Since July 26, 2021, the Company’s common shares are traded under the trading symbol “CYTO”.

These condensed consolidated interim financial statements comprise the Company and its subsidiaries (together referred to as the “Group” and individually as “Group entities”). The Company is the ultimate parent of the following Group entities:

●

Auris Medical AG, Basel, Switzerland (100%) with a nominal share capital of CHF 2,500,000

●

Otolanum AG, Zug, Switzerland (100%) with a nominal share capital of CHF 100,000

●

Altamira Therapeutics, Inc., Dover, Delaware, United States (100%) with a nominal share capital of USD 100

●

Auris Medical Ltd., Dublin, Ireland (100%) with a nominal share capital of EUR 100

●

Zilentin AG, Zug, Switzerland (100%) with a nominal share capital of CHF 100,000

●

Auris Medical Pty Ltd, Collingwood, Australia (100%) with a nominal share capital of AUD 100

●

Altamira Medica AG, Zug, Switzerland (100%) with a nominal share capital of CHF 3,000,000

The Group is primarily involved in the development of novel products that address important unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics. The Group is focusing on the development of RNA therapeutics for extrahepatic therapeutic targets (AM-401), nasal sprays for protection against airborne viruses and allergens (AM-301; Bentrio™) or the treatment of vertigo (AM-125), and the development of therapeutics for intratympanic treatment of tinnitus or hearing loss (AM-101; Keyzilen® and AM-111; Sonsuvi®).

Basis of Preparation (Details)		6 Months Ended
Basis of Preparation (Details)	Jun. 01, 2021	Jun. 30, 2021 CHF (SFr)	Jun. 30, 2021 USD ($)
Disclosure of basis of preparation of financial statements [text block] [Abstract]
Reduction of nominal value, description		The annual general assembly of the shareholders held on June 4, 2020, agreed to reduce the nominal value of the Company’s common share from CHF 0.40 to CHF 0.01.	The annual general assembly of the shareholders held on June 4, 2020, agreed to reduce the nominal value of the Company’s common share from CHF 0.40 to CHF 0.01.
Acquire share capital	100.00%
Purchase price		The purchase price for Trasir comprised: (i) 764,370 non-registered common shares of the Company, par value CHF 0.01 per share, calculated based on a value of USD 2,500,000 divided by the average closing price of the Common Shares on the 15 trading days preceding the closing date (the “Reference Price”, which amounted to USD 3.27 per Common Share); (ii) contingent on the occurrence of positive results from a subsequent post-closing scientific study led by Trasir (“Positive Results”), USD 1,500,000 of common shares of the Company to be calculated based on the average closing price of the common shares on the 15 trading days preceding the occurrence of Positive Results; and (iii) USD 210,000 for expenses incurred by certain selling Trasir shareholders paid in USD 180,000 in cash and 9,173 non-registered common shares based on the Reference Price.	The purchase price for Trasir comprised: (i) 764,370 non-registered common shares of the Company, par value CHF 0.01 per share, calculated based on a value of USD 2,500,000 divided by the average closing price of the Common Shares on the 15 trading days preceding the closing date (the “Reference Price”, which amounted to USD 3.27 per Common Share); (ii) contingent on the occurrence of positive results from a subsequent post-closing scientific study led by Trasir (“Positive Results”), USD 1,500,000 of common shares of the Company to be calculated based on the average closing price of the common shares on the 15 trading days preceding the occurrence of Positive Results; and (iii) USD 210,000 for expenses incurred by certain selling Trasir shareholders paid in USD 180,000 in cash and 9,173 non-registered common shares based on the Reference Price.
Aggregate total sales (in Dollars) \| $			$ 4,375,000
Estimated fair value		SFr 269,700
License acquired amount		3,713,336
Transaction costs		198,246
Capitalization of development costs		3,713,336
Program in amount		SFr 1,715,536

Capital and Reserves (Details)						1 Months Ended					6 Months Ended			12 Months Ended
Capital and Reserves (Details)	Jun. 02, 2021 USD ($) shares	Dec. 03, 2020	Dec. 01, 2020	May 15, 2019 CHF (SFr)	May 02, 2018 CHF (SFr)	Apr. 23, 2020	Jul. 17, 2018	Jan. 30, 2018 SFr / shares shares	Jan. 30, 2018 $ / shares shares	Feb. 21, 2017	Jun. 30, 2021 CHF (SFr) shares	Jun. 30, 2021 USD ($) shares	Jun. 30, 2020 CHF (SFr) shares	Dec. 31, 2020 CHF (SFr)	Jun. 30, 2020 USD ($)
Capital and Reserves (Details) [Line Items]
Issued shares (in Shares) \| shares											13,643,130	13,643,130	5,059,084
Amount of stock \| SFr											SFr 136,431.30		SFr 50,590.84
Upfront acquisition price (in Dollars) \| $	$ 2,500,000
Non registered common shares (in Shares) \| shares	764,370
Reference price (in Dollars) \| $	$ 3.27
Additional non registered price (in Shares) \| shares	9,173
Additional reference price (in Dollars) \| $	$ 30,000
Description of public offering			the convertible loan provided by FiveT in the amount of CHF 895,455 was converted into 737,000 common shares at a conversion price of USD 1.35. On March 4, 2021, the remaining convertible loan by FiveT in the amount of CHF 604,545 plus accumulated interests of CHF 40,268 was converted into 516,814 common shares at a conversion price of USD 1.35.	the Company completed a public offering of (i) 440,000 common shares with a par value of CHF 0.40 each, together with warrants to purchase 440,000 common shares, and (ii) 1,721,280 pre-funded warrants, with each pre-funded warrant exercisable for one common share, together with warrants to purchase 1,721,280 common shares, including 110,000 common shares and warrants to purchase 110,000 common shares sold pursuant to a partial exercise by the underwriters of the underwriters’ over-allotment option (the “May 2019 Registered Offering”). The exercise price for the pre-funded warrants is CHF 0.01 per common share and for the warrants is CHF 4.34. The net proceeds to us from the May 2019 Registered Offering were approximately USD 7.6 million, after deducting underwriting discounts and other offering expenses payable by us. As of December 31, 2019, all pre-funded warrants were exercised. In December 2020, 1,263,845 warrants were exercised; the remaining 897,435 warrants were exercised in March 2021.			the Company completed a public offering of 897,435 common shares with a nominal value of CHF 0.40 each, Series A warrants each entitling its holder to purchase 0.35 of a common share for an aggregate of 314,102 common shares, and Series B warrants entitling its holder to purchase 0.25 of a common share for an aggregate of 224,358 common shares (the “July 2018 Registered Offering”). The exercise price for both series Warrants at the time of the July 2018 Registered Offering was CHF 7.80 per common share. In accordance with the terms of certain Series B warrants, the exercise price for certain Series B warrants was reduced in two steps to ultimately CHF 1.47. The net proceeds to the Company from the July 2018 Registered Offering were approximately CHF 6.2 million, after deducting underwriting discounts and other offering expenses payable by us.			in connection with a public offering of 62,499 common shares, the Company issued 50,000 warrants, each warrant entitling its holder to purchase 0.70 of a common share at an exercise price of USD 240 per common share. Additionally, the underwriter was granted a 30-day option to purchase up to 7,500 additional common shares and/or 7,500 additional warrants, of which the underwriter partially exercised its option for 6,750 warrants.
Securities purchase agreements description		the Company entered into securities purchase agreements with several institutional investors for the purchase and sale of 2,000,000 common shares at an offering price of USD 4.00 per share, pursuant to a registered direct offering. The net proceeds of the offering were approximately USD 7.3 million.
Purchase agreement, description						the Company entered into a purchase agreement and a Registration Rights Agreement with Lincoln Park Capital Fund, LLC (the “2020 Commitment Purchase Agreement”). Pursuant to the purchase agreement, LPC agreed to subscribe for up to USD 10,000,000 of our common shares over the 30-month term of the purchase agreement. Until June 30, 2021, we issued 1,200,000 of our common shares to LPC for an aggregate amount of USD 1,108,155.
Transaction costs \| SFr				SFr 868,296
Transaction costs \| SFr													SFr 3,335
Warrants [Member]
Capital and Reserves (Details) [Line Items]
Issuance initial public offering \| shares (in Shares) \| shares								62,499	62,499
Nominal value per share \| SFr / shares (in Francs per share) \| SFr / shares								SFr 0.40
Warrants total \| shares (in Shares) \| shares								37,499	37,499
Warrants exercisable \| shares (in Shares) \| shares								37,499	37,499
Warrants exercise price per common share \| SFr / shares (in Dollars per share) \| $ / shares									$ 100.00
Fair value of warrants issued \| SFr											19,058
Changes in fair value of warrants issued \| SFr											SFr 12,740			SFr 6,318
Fair value of warrants, description											the fair value of the warrants amounted to zero, unchanged from of December 31, 2020 and from December 31, 2019. Since its initial recognition, the fair value decreased by its initial value of CHF 5,091,817, resulting in a gain in the same amount	the fair value of the warrants amounted to zero, unchanged from of December 31, 2020 and from December 31, 2019. Since its initial recognition, the fair value decreased by its initial value of CHF 5,091,817, resulting in a gain in the same amount
AGP Sales Agreement [Member]
Capital and Reserves (Details) [Line Items]
Common shares for an aggregate (in Shares) \| shares											1,758,618	1,758,618
Aggregate offering price (in Dollars) \| $												$ 2,900,000
Common shares sold \| shares (in Shares) \| shares													202,806
Aggregate purchase price (in Dollars) \| $															$ 3,200,000
LPC Agreement [Member]
Capital and Reserves (Details) [Line Items]
Purchase agreement, description					Company entered into a purchase agreement (the “2018 Commitment Purchase Agreement”) and a registration rights agreement (the “2018 Registration Rights Agreement”) with Lincoln Park Capital Fund, LLC (“LPC”). Pursuant to the 2018 Commitment Purchase Agreement, LPC agreed to purchase common shares for up to USD 10,000,000 over the 30-month term of the 2018 Commitment Purchase Agreement. As of April 7, 2020, the Company has issued 2,820,000 common shares for aggregate proceeds of USD 1.8 million under the 2018 LPC Agreement.
Transaction costs \| SFr					SFr 349,907
Non current assets \| SFr					252,351
Finance expenses \| SFr					SFr 97,556

Label	Element	Value
ShareBasedAssetPurchase	ears_ShareBasedAssetPurchase	SFr 7,735
ShareBasedAssetPurchase	ears_ShareBasedAssetPurchase	2,266,735
ShareBasedAssetPurchase	ears_ShareBasedAssetPurchase	1,078,800
ShareBasedAssetPurchase	ears_ShareBasedAssetPurchase	3,353,270
ShareBasedAssetPurchase	ears_ShareBasedAssetPurchase
ComprehensiveIncomeLoss	ears_ComprehensiveIncomeLoss	16,396
ComprehensiveIncomeLoss	ears_ComprehensiveIncomeLoss	(2,736,511)
ComprehensiveIncomeLoss	ears_ComprehensiveIncomeLoss	(2,720,115)
ComprehensiveIncomeLoss	ears_ComprehensiveIncomeLoss	(41,922)
ComprehensiveIncomeLoss	ears_ComprehensiveIncomeLoss	(6,305,633)
ComprehensiveIncomeLoss	ears_ComprehensiveIncomeLoss	(6,347,555)
ComprehensiveIncomeLoss	ears_ComprehensiveIncomeLoss
ComprehensiveIncomeLoss	ears_ComprehensiveIncomeLoss
ComprehensiveIncomeLoss	ears_ComprehensiveIncomeLoss
ComprehensiveIncomeLoss	ears_ComprehensiveIncomeLoss
ConversionOfLoanin	ears_ConversionOfLoanin	5,168
ConversionOfLoanin	ears_ConversionOfLoanin	1,366,087
ConversionOfLoanin	ears_ConversionOfLoanin	1,371,255
ConversionOfLoanin	ears_ConversionOfLoanin
ConversionOfLoanin	ears_ConversionOfLoanin
AdjustmentsForIncreaseDecreaseInPrepayments	ears_AdjustmentsForIncreaseDecreaseInPrepayments	(66,403)
AdjustmentsForIncreaseDecreaseInPrepayments	ears_AdjustmentsForIncreaseDecreaseInPrepayments	235,388
CapitalIncreaseFromFollowOnOffering	ears_CapitalIncreaseFromFollowOnOffering	373,255
CapitalIncreaseFromFollowOnOffering	ears_CapitalIncreaseFromFollowOnOffering	624,744
CapitalIncreaseFromFollowOnOffering	ears_CapitalIncreaseFromFollowOnOffering	997,999
CapitalIncreaseFromFollowOnOffering	ears_CapitalIncreaseFromFollowOnOffering
CapitalIncreaseFromFollowOnOffering	ears_CapitalIncreaseFromFollowOnOffering
TransactionsCost	ears_TransactionsCost	(3,335)
TransactionsCost	ears_TransactionsCost
TransactionCosts	ears_TransactionCosts	219,615
TransactionCosts	ears_TransactionCosts
ReductionOfTheNominalValue	ears_ReductionOfTheNominalValue	(1,973,044)
ReductionOfTheNominalValue	ears_ReductionOfTheNominalValue	1,973,044
ReductionOfTheNominalValue	ears_ReductionOfTheNominalValue
ReductionOfTheNominalValue	ears_ReductionOfTheNominalValue
ReductionOfTheNominalValue	ears_ReductionOfTheNominalValue
CapitalIncreaseExerciseOfWarrants	ears_CapitalIncreaseExerciseOfWarrants	8,974
CapitalIncreaseExerciseOfWarrants	ears_CapitalIncreaseExerciseOfWarrants	3,885,764
CapitalIncreaseExerciseOfWarrants	ears_CapitalIncreaseExerciseOfWarrants	3,894,738
CapitalIncreaseExerciseOfWarrants	ears_CapitalIncreaseExerciseOfWarrants
CapitalIncreaseExerciseOfWarrants	ears_CapitalIncreaseExerciseOfWarrants
ChangeInOutstandingLoans	ears_ChangeInOutstandingLoans	50,000
ChangeInOutstandingLoans	ears_ChangeInOutstandingLoans	(50,000)
TransactionsCosts	ears_TransactionsCosts	(219,615)
Net Income (Loss) Attributable to Parent	us-gaap_NetIncomeLoss	(2,658,501)
Net Income (Loss) Attributable to Parent	us-gaap_NetIncomeLoss	(2,658,501)
Net Income (Loss) Attributable to Parent	us-gaap_NetIncomeLoss	(6,754,579)
Net Income (Loss) Attributable to Parent	us-gaap_NetIncomeLoss	(6,754,579)
Net Income (Loss) Attributable to Parent	us-gaap_NetIncomeLoss
Net Income (Loss) Attributable to Parent	us-gaap_NetIncomeLoss
Net Income (Loss) Attributable to Parent	us-gaap_NetIncomeLoss
Net Income (Loss) Attributable to Parent	us-gaap_NetIncomeLoss
Net Income (Loss) Attributable to Parent	us-gaap_NetIncomeLoss
Net Income (Loss) Attributable to Parent	us-gaap_NetIncomeLoss
Short-term Debt	us-gaap_ShortTermBorrowings	523,920
Short-term Debt	us-gaap_ShortTermBorrowings
AdjustmentsForIncreaseDecreaseInAccruedExpenses	ears_AdjustmentsForIncreaseDecreaseInAccruedExpenses	78,646
AdjustmentsForIncreaseDecreaseInAccruedExpenses	ears_AdjustmentsForIncreaseDecreaseInAccruedExpenses	(147,334)
TransactionCost	ears_TransactionCost	(3,335)
TransactionCost	ears_TransactionCost	(3,335)
TransactionCost	ears_TransactionCost
TransactionCost	ears_TransactionCost
TransactionCost	ears_TransactionCost

Taxation (Details) - Schedule of income tax expense - CHF (SFr)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Schedule of income tax expense [Abstract]
Deferred income tax expense
Deferred income tax gain	SFr 10,642	SFr 10,642

Taxation (Details) - Schedule of deferred income tax liabilities or to deferred income tax assets - CHF (SFr)	Jun. 30, 2021	Jun. 30, 2020
Deferred Tax assets
Deferred Tax, net	SFr (115,222)	SFr (136,507)

Loan (Details) - CHF (SFr)		6 Months Ended
Loan (Details) - CHF (SFr)	Sep. 08, 2020	Jun. 30, 2021	Mar. 26, 2020
Disclosure Of Loan [Abstract]
Granted loan amount			SFr 50,000
Principal amount	SFr 1,500,000
Interest		SFr 8,348
Amortization transaction costs		SFr 162,546

Capital and Reserves (Details) - Schedule of issued share capital - shares	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Schedule of issued share capital [Abstract]
Common shares issued	2,225,971	933,135

Employee Benefits (Details)	6 Months Ended
Employee Benefits (Details)	Jun. 30, 2021 CHF (SFr) shares	Jun. 30, 2021 USD ($) shares	Jun. 30, 2020 CHF (SFr) shares	Jun. 30, 2020 USD ($) shares
Disclosure of employee benefits [text block] [Abstract]
Share based compensation expense	SFr 810,252
Stock options	159,487		SFr 167,908
Share based payments total	1,044,912
Share based compensation expense	969,739		SFr 167,908
Employees shares issued	92,566
Deduction amount	SFr 21,990
Granted options (in Shares) \| shares	137,236	137,236	433,030	433,030
Employee benefits incentive plan (in Dollars) \| $		$ 3.51		$ 0.83

Employee Benefits (Details) - Schedule of employee benefits - CHF (SFr)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Schedule of employee benefits [Abstract]
Share based compensation expense	SFr 969,739	SFr 167,908

Loss Per Share (Details)	Sep. 07, 2021 shares
Stock Options [Member]
Loss Per Share (Details) [Line Items]
Options outstanding	1,146,854

Loss Per Share (Details) - Schedule of loss per share - CHF (SFr)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Schedule of loss per share [Abstract]
Loss attributable to owners of the Company	SFr (6,754,579)	SFr (2,658,501)
Basic and diluted loss per share	SFr (0.54)	SFr (0.58)